4.5 Review

Targeting Signalling Pathways in Hepatocellular Carcinoma

Journal

CURRENT PHARMACEUTICAL DESIGN
Volume 23, Issue 1, Pages 170-175

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612822666161006160005

Keywords

Hepatocellular carcinoma; hepatocarcinogenesis; genomics; signalling pathway; drug targets; microRNA

Funding

  1. Slovenian Research Agency (ARRS) program [P1-0390]
  2. graduate fellowship of ARRS

Ask authors/readers for more resources

Background: Hepatocellular carcinoma (HCC) represents the most common malignant liver tumor in humans, which incidence and mortality have increased in Europe and United States in the last years. Most patients are diagnosed at an advanced stage, when it is not amenable to curative therapies, so there is an urgent need for new, more effective therapeutic tools and strategies. The molecular mechanisms of hepatocarinogenesis and HCC progression have been increasingly understood with intense research in recent years. Methods: The goal of this work is to discuss the different signalling pathways as important potential therapeutic targets. Results: Disruption of pathways known to play roles in HCC, such as Wnt/beta-catenin, Hedgehog, RAF/MEK/ERK, tryosine kinase receptor-related pathway, Met-HGF, VEGF/ VEGF and ROR signalling pathways may be seminal for liver oncogenesis. Conclusion: This review reveals that oncogenes, especially microRNAs that are conserved across species and interfere with signalling pathways might be used as promising strategies for halting or reversing the progression of HCC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available